RxDoctor Payments DataLook up a doctor →

Robert Oberstein, MD

Endocrinology, Diabetes & Metabolism · Hartford, CTNPI 1568404267

Payments from drug & device makers

$516,043in general payments, 2019–2025

Across 1,656 payments — averaging $311.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$308K
  • Abbott$78K
  • Novo Nordisk$62K
  • AstraZeneca$32K
  • Boehringer Ingelheim$15K
  • Ascendis Pharma Endocrinology Inc$8K
  • plus $13K from 39 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC762$307,540
Abbott239$77,603
Novo Nordisk241$62,218
AstraZeneca77$31,975
Boehringer Ingelheim41$15,344
Ascendis Pharma Endocrinology Inc5$8,315
Merck17$4,966
Tandem Diabetes Care, Inc.11$1,720
Dexcom, Inc.53$1,574
Amgen(2 entities)60$1,431
AbbVie23$397
Sanofi-aventis U.S. LLC21$367
Corcept Therapeutics10$365
Xeris Pharmaceuticals, Inc.8$250
Medtronic(2 entities)6$217
Amneal Pharmaceuticals LLC13$215
Sequel Med Tech, LLC2$186
Senseonics, Incorporated2$149
Insulet Corporation7$143
Lifescan, Inc.7$132
Amarin Pharma, Inc.6$95
Johnson & Johnson5$83
Antares Pharma, Inc.4$70
Companion Medical, Inc.3$55
IBSA Pharma Inc.3$53
Endo Pharmaceuticals Inc.3$51
Radius Health, Inc.3$51
Novartis2$44
BETA Bionics, Inc.2$43
Aytu Biopharma, Inc.3$40
Halozyme Inc2$36
Bayer1$32
Cequr Corporation1$31
Zealand Pharma US, Inc.1$30
Kowa Pharmaceuticals America, Inc.2$28
Intra-sana Laboratories1$25
Almatica Pharma LLC1$22
Neurocrine Biosciences, Inc.1$21
Ipsen Biopharmaceuticals, Inc1$21
Takeda Pharmaceuticals U.S.A., Inc.1$21
BD1$20
Acerus Pharmaceuticals Corporation1$19
Alfasigma USA, Inc.1$16
Shire North American Group Inc1$15
Pfizer1$11

How this compares

$516,043 in reported general payments places this provider in the 95th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.

See all endocrinology, diabetes & metabolism providers in Connecticut →

Medicare billing

Part B allowed, 2024
$299,255
Medicare patients
423
Services billed
9,173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Hartford

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →